T-5224 is a small-molecule c-Fos/activator protein 1 (AP-1) inhibitor which was under development for the treatment of rheumatoid arthritis but was never marketed. It is taken orally. The drug was under development by Toyama Chemical. It reached phase 2 clinical trials prior to the discontinuation of its development. T-5224 has been found to selectively inhibit FOS-containing AP-1 complexes. An analogous kind of approach might be useful for targeting a subset of ΔFosB-associated complexes to treat conditions like addiction. The activity of T-5224 itself against ΔFosB is unknown.
References


